Is Money Being Wasted on Syndrome's Treatment?

There's been a lot of criticism of the Consumer Reports (CR) Adwatch video segment that satirized the ubiquitous Requip TV ad (see this post to Pharma Marketing Blog). Requip is a GSK drug approved in 2005 for the treatment of "Restless Leg Sydrome" (RLS).

I have to agree with most of the critics who complained that the CR video was a sophomoric attempt at humor. However, CR reporter Jamie Hirsh did make one point that most critics have glossed over: 57% of sufferers get better with placebo compared to 73% on Requip.

This raises the question: Is money being wasted on the treatment of RLS? Let me whip out my trusty Microsoft desktop calculator and do some math so that you don't have to.

For the math, read today's post to Pharma Marketing Blog.

For more posts in related topic areas, see:

• DTC Advertising

If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.

The collection of articles and commentary in this first Pharma Marketing News Special Supplement chronicles the emerging issues of direct-to-consumer (DTC) advertising and presents pro and con opinions from experts on how DTC needs to adapt in the post-Vioxx marketing era. Topics include: DTC Pros and Cons, Straight-Talking DTC, Communicating Risk, Biotech DTC, Print DTC, and more.

TABLE OF CONTENTS

Order both Volume One and Volume Two and SAVE! (Click Here)

Order and pay for Volume One now using your credit card

ONLY $29.95
PDF file delivered to you by email (usually within minutes of placing your order):

If you wish to be pay by check or credit card off-line, please use:
Printable Order Form